326 Принципы и практика психофармакотерапии

27. Preskorn S, Burke M. Somatic therapy for major depressive disorder: selection of an antidepres-sant. J Clin Psychiatry 1992; 53 (Suppl 9): 5-18.

28. Bolden-Watson C, Richelson E. Blockade by new­ly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52:1023-1029.

29. Cusack B, Nelson A, Richelson E. Binding of anti-depressants to human brain receptors: focus on newer generation compounds. Psychopharmaco-logy 1994; 114: 559-565.

30. Klamerus KJ, Maloney K, Rudolph RL, Sisenwi-ne SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active 0-desmethyl metabo­lite. J Clin Pharmacol 1992; 32: 716-724.

31. Troy S, Piergies A, Lucki I, Parker V, Chiang S. Venlafaxine pharmacokinetics and pharmacody-namics. Clin Neuropharmacol 1992; 15 (Suppl 1): 324B.

32. Preskorn SH. Pharmacokinetic profile of Effexor (venlafaxine HCI) [Unpublished], 1994.

33. Haskins JT, Moyer JA, Muth EA, Sigg EB. DMI, WY-45,030, WY-45,881 and ciramadol inhibit locus coeruleus neuronal activity. Eur J Pharmacol 1985; 115:139-146.

34. Guelfi JD, White C, Magni G. A randomized, dou­ble-blind comparison of venlafaxine and place­bo in inpatients with major depression and me­lancholia [Abstract]. Clin Neuropharmacol 1992; 15 (Suppl 1):323B.

35. Preskorn S. Antidepressant drug selection: crite­ria and options.) Clin Psychiatry 1994; 55(Suppl 9A): 6-22.

36. Rudolph R, Entsuah R, Derivan A. Early clinical response in depression to venlafaxine hydrochlo-ride [Abstract]. Biol Psychiatry 1991; 29 (Suppl 11):630S.

37. Rickels K, Derivan A, Rudolph RL. Venlafaxine: rapid onset of antidepressant activity. American College of Neuropsychopharmacology 29th An­nual Meeting, Dec. 10-14, 1990, San Juan, PR. 1990; 141.

38. Derivan A, Entsuah R, Rudolph R, Rickels K. Early response to venlafaxine hydrochloride, a novel anti-depressant. American Psychiatric Association 145th Annual Meeting, May 2-7,1992, Washing­ton, DC. 1992: 82-83.

39- Venlafaxine presentation to the Food and Drug Administration Psychopharmacology Advisory Committee. Washington DC, April 1993.

40. Baron B, Ogden A, Siegel B, et al. Rapid down regulation of adrenoceptors by coadministration of desipramine and fluoxetine. Pharmacol 1988; 154:125-134.

41. Nierenberg AA, Feighner JF, Rudolph RR, Cole JO, Sullivan J. Venlafaxine for treatment-resistant depression. Neuropsychopharmacology 1994;

10 (Suppl 2): 85S.

42. Fontaine R, Ontiveros A, Faludi G, Elie R, Roberts D, Ecker J. A study of nefazodone, imipramine, and placebo in depressed outpatients. Biol Psychia­try 1991; 29: П8А.

43. Feighner JP, Pambakian R, Fowler RC, Boyler WF, D'Amico ME A comparison of nefazodone, imi­pramine and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989; 25:219-221.

44. Fontaine R, Ontiveros A, Faludi G, Elie R, Roberts D, Ecker J. A study of nefazodone, imipramine, and placebo in depressed outpatients. Biol Psychia­try 1991; 29: И8А.

45. Weise C, Fox I, Clary C, Schweizer E, Rickels K. Nefazodone in the treatment of outpatient ma­jor depression. Biol Psychiatry 1991; 29: 363S.

46. Yocca FD, Hyslop DK, Taylor DP. Nefazodone: a potential broad spectrum antidepressant. Trans Am Soc Neurochem 1985; 16:115.

47. Robinson D, Roberts D, Archibald D, Anton S, Kensler T, Gammans R. Therapeutic dose range of nefazodone for the treatment of major depres­sion. J Clin Psychiatr 1996; 57 (Suppl 2): 6-9.

48. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychia­try 1994; 55:6: 234-241.

49. Nafazodone presentation to the Food and Drug Administration Psychopharmacology Advisory Committee. Washington DC, July 1993.

50. Mendels J, Reimherr F, Marcus R, Roberts D, Fran­cis R, Anton S. A double-blind, placebo-control­led trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychi­atry 1995; 56 (Suppl 6): 30-36.

51. D'Amico M, Roberts D, Robinson D, et al. Place­bo-controlled dose-ranging trial designs in phase

11 development of nefazodone. Psychopharmacol Bull 1990; 26:147-150.

52. Feighner J, Pambakian R, Fowler R, et al. A com­parison of nefazodone, imipramine and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989; 25: 219-221.